Document is current

Article History

Received: 18 September 2025

Revised: 28 January 2026

Accepted: 2 February 2026

First Online: 4 May 2026

Declarations

: No funding was received to conduct this study and/or the manuscript preparation. Dr. Aparasu has received research funding from Astellas Inc., Incyte Corp., Gilead, and Novartis Inc. for projects unrelated to the current study. We confirm the originality of this work, stating that the complete study report has not been previously published or is currently under consideration for publication elsewhere Part of the study findings were presented at the Geriatric Medication Safety Symposium and published as a conference abstract at https://www.sciencedirect.com/journal/research-in-social-and-administrative-pharmacy/vol/21/issue/11?page=3.

: The MEPS data is de-identified and completely compliant with the Health Insurance Portability and Accountability Act (HIPAA); hence, the University of Houston Institutional Review Board classified the research as exempt from human subjects’ review.

: The authors declare no competing interests.